Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Gains from Sales and Divestitures (2020 - 2026)

Kymera Therapeutics (KYMR) has disclosed Gains from Sales and Divestitures for 7 consecutive years, with $189052.0 as the latest value for Q1 2026.

  • For Q1 2026, Gains from Sales and Divestitures rose 28.72% year-over-year to $189052.0; the TTM value through Mar 2026 reached $189052.0, up 28.72%, while the annual FY2025 figure was $284026.0, 62.8% up from the prior year.
  • Gains from Sales and Divestitures hit $189052.0 in Q1 2026 for Kymera Therapeutics, down from $284026.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $284026.0 in Q4 2025 and bottomed at $14215.0 in Q1 2022.
  • Average Gains from Sales and Divestitures over 5 years is $115720.4, with a median of $83209.0 recorded in 2024.
  • Year-over-year, Gains from Sales and Divestitures tumbled 56.56% in 2022 and then soared 371.47% in 2024.
  • Kymera Therapeutics' Gains from Sales and Divestitures stood at $36866.0 in 2022, then increased by 7.17% to $39511.0 in 2023, then skyrocketed by 341.56% to $174463.0 in 2024, then surged by 62.8% to $284026.0 in 2025, then crashed by 33.44% to $189052.0 in 2026.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $189052.0, $284026.0, and $278130.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.